When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)

Leukemia Research

Volumn 33, Issue 9, 2009, Pages 1178-1182

  Cassinat, Bruno ^a   de Botton, Stéphane ^b,d   Kelaidi, Charikleia ^c   Ades, Lionel ^c   Zassadowski, Fabien ^a   Guillemot, Isabelle ^a   Schlageter, Marie Helene ^a   Raffoux, Emmanuel ^a   Harousseau, Jean Luc ^e   Legrand, Olivier ^f   Escoffre Barbe, Martine ^g   Reman, Oumedaly ^h   Gardembas, Martine ⁱ   Himberlin, Chantal ^j   Cahn, Jean Yves ^k   Guyotat, Denis ^l   Bouscary, Didier ^m   Parry, Anne ⁿ   Rousselot, Philippe ^o   Baruchel, Andre ^a   Dombret, Hervé ^a   Chevret, Sylvie ^a   Fenaux, Pierre ^c   Chomienne, Christine ^a   more..

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c AVICENNE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h CAEN UNIVERSITY HOSPITAL   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j REIMS UNIVERSITY HOSPITAL   (France)

^k GRENOBLE UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^m Hopital de Versailles ^*  (France)

ⁿ Hopital de Roubaix   (France)

^o CENTRE HOSPITALIER DE VERSAILLES   (France)

more..

Author keywords

APL; Minimal residual disease; Prognosis; Relapse; RQ PCR

Indexed keywords

ANTHRACYCLINE; CYTARABINE; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE;

HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; ONCOGENE PROTEINS, FUSION; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 67549088250     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.010     Document Type: Article

References (22)

1. Grimwade D., Biondi A., Mozziconacci M.J., Hagemeijer A., Berger R., Neat M., et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 96 (2000) 1297-1308
2. Asou N., Adachi K., Tamura J., Kanamaru A., Kageyama S., Hiraoka A., et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 16 (1998) 78-85
3. Sanz M.A., Lo Coco F., Martin G., Avvisati G., Rayón C., Barbui T., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA Cooperative Groups. Blood 96 (2000) 1247-1253
4. Fenaux P., Chomienne C., and Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 38 (2001) 13-25
5. Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukaemia. The European APL Group. Blood 94 (1999) 1192-1200
6. Sanz M.A., Tallman M.S., and Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 105 (2005) 3019-3025
7. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Woods W.G., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol. Blood 100 (2002) 4298-4302
8. Diverio D., Rossi V., Avvisati G., De Santis S., Pistilli A., Pane F., et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 92 (1998) 784-789
9. Mandelli F., Diverio D., Avvisati G., Luciano A., Barbui T., Bernasconi C., et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 90 (1997) 1014-1021
10. Jurcic J.G., Nimer S.D., Scheinberg D.A., DeBlasio T., Warrell Jr. R.P., and Miller Jr. W.H. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 98 (2001) 2651-2656
11. Grimwade D., and Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 16 (2002) 1959-1973
12. Gallagher R.E., Yeap B.Y., Bi W., Livak K.J., Beaubier N., Rao S., et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 101 (2003) 2521-2528
13. Schnittger S., Weisser M., Schoch C., Hiddemann W., Haferlach T., and Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 102 (2003) 2746-2755
14. Santamaria C., Chillon M.C., Fernandez C., Martin-Jimenez P., Balanzategui A., Garcia Sanz R., et al. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica 92 (2007) 315-322
15. Tobal K., and Liu Yin J.A. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia 12 (1998) 1349-1354
16. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Berger R., Fenaux P., et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukaemia. I. Clinical results. Blood 76 (1990) 1704-1709
17. Cassinat B., Zassadowski F., Balitrand N., Barbey C., Rain J.D., Fenaux P., et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 14 (2000) 324-328
18. Ades L., Chevret S., Raffoux E., de Botton S., Guerci A., Pigneux A., et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24 (2006) 5703-5710
19. Weisser M., Kern W., Rauhut S., Schoch C., Hiddemann W., Haferlach T., et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19 (2005) 1416-1423
20. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-3360
21. Cassinat B., and Chomienne C. Future perspectives for acute promyelocytic leukemia therapy. Semin Hematol 38 (2001) 86-91
22. Tallman M.S. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 20 (2007) 57-65